Cytokinetics Inc (CYTK) financials
Cytokinetics revenue and earnings by year
Cytokinetics's revenue was $88.0 million in the fiscal year to December 31, 2025, up 376.6% from the year before. Net income was -$785 million, -891.6% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 2.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88 | 18 | 8 | 95 | 70 | 56 | 27 | 32 | 13 | 106 |
| Revenue growth | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | 107.8% | -14.7% | 135.6% | -87.4% | — |
| Operating income | -612 | -536 | -496 | -324 | -186 | -94 | -99 | -89 | -113 | 19 |
| Operating margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% |
| Net income | -785 | -590 | -526 | -389 | -215 | -127 | -122 | -106 | -128 | 16 |
| Net margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% |
| Diluted EPS | -$6.54 | -$5.26 | -$5.45 | -$4.33 | -$2.79 | -$2.02 | -$2.11 | -$1.95 | -$2.59 | $0.33 |
| Free cash flow | -535 | -400 | -416 | -311 | -191 | -2 | -94 | -102 | -105 | 35 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CYTK in Markets.
How Cytokinetics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Net Product Revenue | $25.3M | 88.5% |
| Collaboration Revenues | $3.29M | 11.5% |
See also: CYTK returns
No forecast, no recommendation. This page describes Cytokinetics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.